Sionna Therapeutics, Inc.

NASDAQ:SION

Biotechnology

Healthcare
$2.97 +1.85%

+$0.68 today

Market cap
$134.35M
Beta
1.29
P/E (TTM)
-19.7
EPS (TTM)
-$1.90
52W Low $13.81High $48.45

Volume 0.65M

Average 0.39M

Returns on capital

Sionna Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-24.5%

avg 28.0%

ROIC

-28.2%

avg -58.3%

ROA

-23.1%

avg -48.3%

Analysis

ROA is currently the strongest return metric at -23.1% versus its period average of -48.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael Cloonan

President, Chief Executive Officer & DirectorUSD 1.03M550<0.01%

Elena H. Ridloff

CFO & Chief Business OfficerUSD 771.6K46——

Charlotte McKee

Chief Medical Officer & Head of Research and DevelopmentUSD 647.92K610<0.01%

Caroline Stark Beer

Chief Business OfficerUSD 268.11K47139.34K0.31%

Mark Munson

Co-founder————

Roxanne McGrath

Vice President of Head of Human Resources————

Juliet Labadorf

Senior Director of Investor Relations & Corporate Development————

Kenneth A. Lock

Chief Commercial Officer—52——

Mark Trone

Senior VP & Head of CMC————

Cecile Le Camus

VP & Head of Medical Affairs————

Erica Iorio

VP of Finance & Controller————

Jennifer Fitzpatrick

Chief Legal Officer & Head of Program Management—490<0.01%

Mara Furlow

Senior Vice President of Global Regulatory Affairs & Quality————

Meghan Bagshaw

Vice President & Chief of Staff to CMO————

Greg Hurlbut

Co-Founder & Senior Vice President of Discovery Research————

Andy Chu

Vice President of Information & Technology————

Sarah J. Spencer

Vice President of Corporate Communications————

Vanya Sagar

Chief People Officer—50——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

58

$145.59M

Net Transaction Value

−$145.59M

Net selling

Most Active

Thompson Peter A.

20 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 17, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$252.1K
Sep 17, 26

RA CAPITAL MANAGEMENT, L.P.

Indirect

Sell$21.6M
Jul 7, 26

Thompson Peter A.

Indirect

Sell$3.9M
Jul 7, 26

ORBIMED ADVISORS LLC

Indirect

Sell$3.9M
Jul 6, 26

Fitzpatrick Jennifer

Direct

Sell$446.9K
Jun 30, 26

ORBIMED ADVISORS LLC

Indirect

Sell$5.3M
Jun 30, 26

Thompson Peter A.

Indirect

Sell$5.3M
May 27, 26

Thompson Peter A.

Indirect

Sell$4.5K
May 27, 26

ORBIMED ADVISORS LLC

Indirect

Sell$4.5K
May 11, 26

ORBIMED ADVISORS LLC

Indirect

Sell$8.5M

1–10 of 58

Summary

Insiders reported 0 buys worth $0.00 and 58 sells worth $145.59M over the last 12 months. That adds up to net selling of $145.59M. Thompson Peter A. was the most active insider with 20 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A6 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Sionna Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SION's management, answered from reported figures.

Who manages SION?

Sionna Therapeutics, Inc. (SION) lists 18 active executives. The top listed executive is Mark Munson, Co-founder.

Are SION insiders buying or selling?

Recent insider activity shows net selling of $167.67M.